Business Context and Reporting Period
This Form 8-K, dated June 4, 2024, reports on Becton, Dickinson and Company (BD) entering into material definitive agreements to issue new debt securities. The filings relate to three distinct bond offerings executed on June 4, 2024, with issuance occurring on June 7, 2024.
Key Financial Metrics and Debt Issuance
BD raised a total aggregate principal amount of approximately €1.8 billion and $600 million through three new note offerings:
- BD Euro Notes: €1,000,000,000 aggregate principal amount of 3.828% Notes due 2032.
- Becton Finance Notes: €800,000,000 aggregate principal amount of 4.029% Notes due 2036, issued by a Luxembourg subsidiary and fully guaranteed by BD.
- BD USD Notes: $600,000,000 aggregate principal amount of 5.081% Notes due 2029.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as this is a current report regarding debt issuance rather than a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the expansion of BD's debt capital structure. The net proceeds from these offerings, combined with commercial paper borrowings and cash on hand, are designated for the following purposes:
- Funding the cash consideration for the acquisition of the Critical Care business of Edwards Lifesciences Corporation.
- Paying fees and expenses related to the acquisition and the debt offerings.
- General corporate purposes.
The debt offerings are not conditioned upon the consummation of the acquisition, though the filing notes there can be no assurance the acquisition will be completed.
Guidance, Risks, and Unusual Items
Special Mandatory Redemption: Both the Becton Finance Notes and the BD USD Notes contain a "Special Mandatory Redemption" provision. If the acquisition of Edwards Lifesciences' Critical Care business is not consummated by June 3, 2025 (or an extended date), or if BD notifies the trustee it will not pursue the acquisition, BD must redeem these notes at 101% of the principal amount plus accrued interest.
Change of Control: All three note series include provisions requiring BD to offer to repurchase the notes at 101% of the principal amount plus accrued interest if a Change of Control Triggering Event occurs.
Redemption Options: BD retains the option to redeem the notes prior to maturity at a price equal to the greater of 100% of the principal or the present value of remaining payments plus a spread, plus accrued interest.
Risks: The filing explicitly states there is no assurance that the acquisition will be consummated. Additionally, the proceeds are not held in escrow pending the acquisition.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received from the three offerings.
- Monitor the status of the Edwards Lifesciences Critical Care business acquisition to assess the risk of the Special Mandatory Redemption triggering in June 2025.
- Review the impact of the new debt load on BD's leverage ratios and interest coverage in subsequent quarterly reports.
- Confirm the specific terms of the "Outside Date" extension rights regarding the acquisition agreement.